Bluejay Diagnostics (NASDAQ:BJDX) reported quarterly losses of $(0.10) per share.
Woodward Revises FY23 Outlook, Now Sees EPS From $3.15-$3.60 To $3.50-$3.75 Vs 3.18 Est.; Sales From $2.6B-$2.7B To $2.7B-$2.8B Vs $2.64B Est.
Fiscal Year 2023 OutlookWe continue to expect year-over-year improvements in the second half of fiscal 2023. Due to our better-than-expected results experienced in the second quarter as well as an anticipated lower
